Erman Akkus: Adjuvant pembrolizumab after surgery in high risk muscle invasive bladder cancer
Erman Akkus, Medical Oncology fellow at Ankara University, Faculty of Medicine, shared a post on X, about a recent paper by Andrea Apolo et al. published in The New England Journal of Medicine.
“Adjuvant pembrolizumab after surgery (with or without neoadjuvant ChT) in high-risk muscle-invasive bladder cancer NEJM.
- DFS benefit in ITT population
- Subgroup analyses: Not statistically significant in patients without neoadjuvant ChT
- Adjuvant ChT in this group?”
“Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma”
Authors: Andrea Apolo, Karla Ballman, Guru Sonpavde, Michael Morris, Jonathan Rosenberg, et al.
More posts featuring Erman Akkus.
Erman Akkus is a medical oncology fellow at Ankara University, Faculty of Medicine. Previously, he was an Internal Medicine Resident at the Ankara University, Faculty of Medicine. He was also a Visiting Researcher at the University of Oslo. He completed his education at the Medical University of Vienna.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023